COBRA’s headline numbers
14:56–15:52 · 55s
Rahul delivers the punchline: apixaban halves clinically relevant bleeding versus rivaroxaban for acute VTE, with similar VTE recurrence despite lower adherence to BID apixaban.
14:56–15:52 · 55s
Rahul delivers the punchline: apixaban halves clinically relevant bleeding versus rivaroxaban for acute VTE, with similar VTE recurrence despite lower adherence to BID apixaban.
We use cookies to understand how you use our platform and to improve your experience. Click "Accept All" to consent, or "Decline non-essential" to opt out of non-essential cookies. Read our Privacy Policy.